TipRanks on MSN
Zimmer Biomet’s Knee Implant Study: A Market Game-Changer?
Zimmer Biomet Holdings (($ZBH)) announced an update on their ongoing clinical study. The Persona OsseoTi Keel Compatibility Study, officially ...
Zimmer Biomet Holdings (($ZBH)) announced an update on their ongoing clinical study. Zimmer Biomet Holdings has announced a new pilot study, ...
The 2025 calendar year will close off in the next two months with little to celebrate for one of Mamelodi Sundowns’ key defensive pillars.
Five-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, ...
The everolimus scaffold, which had mostly disappeared by 3 years, was still associated with fewer reinterventions than PTA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback